You may be reading this because you or someone you care about has nasal cavity or sinus cancer. Learning more can help you get ready to talk with your healthcare provider and understand the next steps ...

The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to chronic rhinosinusitis. This allows for early prediction of disease ...

People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...

Indication covers kids and adults with a history of sino-nasal surgery ...